Osteoarthritis year 2012 in review: biomarkers  by Mobasheri, A.
Osteoarthritis and Cartilage 20 (2012) 1451e1464Review
Osteoarthritis year 2012 in review: biomarkers
A. Mobasheri*
Musculoskeletal Research Group, School of Veterinary Medicine and Science, Faculty of Medicine and Health Sciences, The University of Nottingham, Sutton Bonington Campus,
Sutton Bonington, LE12 5RD, United Kingdoma r t i c l e i n f o
Article history:
Received 13 May 2012
Accepted 17 July 2012
Keywords:
Osteoarthritis
Articular cartilage
Synovium
Inﬂammation
Biomarker
Biochemical marker
Proteomics
Complement
Chemotactic proteins
Adipokines* Address correspondence and reprint requests to: A
Research Group, School of Veterinary Medicine and
and Health Sciences, The University of Nottingham, Su
5RD, United Kingdom. Tel: 44-115-951-6449; Fax: 44
E-mail address: ali.mobasheri@nottingham.ac.uk.
1063-4584/$ e see front matter  2012 Osteoarthriti
http://dx.doi.org/10.1016/j.joca.2012.07.009s u m m a r y
Purpose: Biomarkers provide useful diagnostic information by detecting cartilage degradation in osteo-
arthritis (OA), reﬂecting disease-relevant biological activity and predicting the course of disease
progression. They also serve as surrogate endpoints in the drug discovery process. The aim of this narrative
reviewwas to focus onOA biomarker-related papers published between the osteoarthritis research society
international (OARSI) 2011 meeting in San Diego and the OARSI 2012 meeting in Barcelona.
Methods: The PubMed/MEDLINE and SciVerse Scopus bibliographic databases were searched using the
keywords: ‘biomarker’ and ‘osteoarthritis’ and/or ‘biomarker’ and ‘proteomics’.
Results: Ninety-eight papers were found with the keywords ‘biomarker’ and ‘osteoarthritis’. Fifteen
papers were found with the keywords ‘biomarker’ and ‘proteomics’. Review articles were also included.
The most relevant published studies focused on extracellular matrix (ECM) molecules in body ﬂuids.
Enrichment of the deamidated epitope of cartilage oligomeric matrix protein (D-COMP) suggests that OA
disease progression is associated with post-translational modiﬁcations that may show speciﬁcity for
particular joint sites. Fibulin-3 peptides (Fib3-1 and Fib3-2) have been proposed as potential biomarkers
of OA along with follistatin-like protein 1 (FSTL1), a new serum biomarker with the capacity to reﬂect the
severity of joint damage. The ‘membrane attack complex’ (MAC) component of complement has also
been implicated in OA.
Conclusion: Novel OA biomarkers are needed for sub-clinical disease diagnosis. Proteomic techniques are
beginning to yield useful data and deliver new OA biomarkers in serum and urine. Combining
biochemical markers with tissue and cell imaging techniques and bioinformatics (i.e., machine learning,
clustering, data visualization) may facilitate the development of biomarker combinations enabling earlier
detection of OA.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of degenerative
joint disease and a leading cause of pain and chronic physical
disability in older individuals1. OA has a multifactorial etiology, and
can be considered the product of interactions between systemic,
mechanical and local factors within the joint2. Although OA is
primarily associated with aging, there are other key contributing
factors, including obesity (which increases mechanical stress and
systemic levels of inﬂammatory mediators such as adipokines3),
a history of joint trauma, repetitive use or injury, genetics, heritable
metabolic disorders, muscle weakness, underlying anatomical and. Mobasheri, Musculoskeletal
Science, Faculty of Medicine
tton Bonington Campus, LE12
-115-951-6440.
s Research Society International. Porthopedic disorders (i.e., congenital hip dislocation), joint infec-
tion, crystal deposition, previous rheumatoid arthritis (RA) and
various disorders of bone turnover and blood clotting. The meta-
bolic alterations that occur in obesity along with biomechanical
factors and pro-inﬂammatory mediators produced by white
adipose tissue in the chronically overweight are thought to be
major factors in the progression of the disease4. Stepwise
approaches to the management of OA have been proposed by
a number of leading investigators. Thus far the evidence suggests
that with the exception of joint replacement, the currently available
treatments are, at best, modestly efﬁcacious, and are frequently
associated with substantial side-effects or costs, or both5. This
highlights, and reinforces, the need for new treatments and
therapeutics.
Articular cartilage loss or damage in OA is detected by radiog-
raphy and measuring decreases in joint space width (JSW) on the
radiograph e the so-called “gold standard”. However, radiographic
evidence is seen only after signiﬁcant cartilage degradation hasublished by Elsevier Ltd. All rights reserved.
Fig. 1. The biomarker pipeline. The discovery of new biomarkers is followed by
independent scientiﬁc and analytical veriﬁcation of the biomarker. This process
involves veriﬁcation of the analytical performance characteristics and clinical corre-
lation of a biomarker with a biological process or clinical outcome. Assay development
and optimization are followed by validation, which involves assessing all the technical
aspects of the biomarker assay. Qualiﬁcation allows biomarker to be linked to a clinical
endpoint to support its use as a surrogate endpoint in drug discovery, development or
post approval and, where appropriate, in regulatory decision-making.
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latent and asymptomatic for many years. Therefore, the “gold
standard” is inadequate and there is an acute need for reliable new
biomarkers and diagnostic tests that can facilitate earlier diagnosis
of OA, and inform the prognosis, monitoring and therapeutic
strategies for chronic and disabling forms of the disease. Most of
the studies carried out to date have focused on late stages of the
disease in humans or animal models. Studies on early stages of OA
are lacking and there are no biomarkers for early diagnosis of the
disease.
The Biomarkers Deﬁnitions Working Groupa deﬁnes
a biomarker as a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion6. Biomarkers can be anatomic, physiologic, biochemical, or
molecular parameters associated with the presence and severity of
speciﬁc diseases and are detectable by a variety of methods,
including physical examination, laboratory assays, and imaging.
Biomarkers are also used as indicators of pharmacologic responses
to therapeutic interventions. In OA biomarkers can be classiﬁed as
“dry” biomarkers or “wet” soluble biomarkers. Dry biomarkers
include imaging parameters (i.e., from radiographs, magnetic
resonance imaging (MRI), and ultrasound), questionnaires and data
fromvisual analog scales. Soluble biomarkers correspond to genetic
(RNA, DNA) and biochemical (carbohydrates, proteins, protein
fragments, peptides, metabolites) molecules7. Biochemical markers
can be measured in blood, serum, urine and synovial ﬂuid.
There is an important relationship between the biomarker and
pharmaceutical pipelines. Biomarker and drug discovery are pro-
tracted, risky and costly. Currently there are many challenges facing
the pharmaceutical sector. The drug pipeline is convoluted, “leaky”
and highly susceptible to recessions and ﬁnancial crises. The
pharmaceutical industry has not managed to bring effective and
safe disease-modifying osteoarthritic drugs (DMOADs) to patients
suffering from this debilitating disease8. The heterogeneity and
slow progressive nature of OA in the human population combined
with prolonged periods of asymptomatic, degenerative changes
have hampered the development of new drugs9. The paucity of
biomarkers has been a key contributor to the lack of progress in this
area because of the mutual interdependency of the drug and
biomarker pipelines.
Currently there are no reliable, quantiﬁable and easily measured
biomarkers that provide an earlier diagnosis of OA, inform on the
prognostic of OA disease and monitor responses to therapeutic
modalities. Linking a biomarker to a clinical endpoint facilitates the
drug discovery process. The process of “qualiﬁcation” in the
biomarker pipeline (Fig. 1) may support the use of suitable
biomarkers as surrogate endpoints in drug discovery and devel-
opment, post approval and regulatory decision-making. Applying
the biomarkers toolbox in drug discovery and development
provides the opportunity to establish quantiﬁable decision points
in the drug pipeline. Biomarkers of joint tissue turnover enable
a more rational and personalized approach to healthcare manage-
ment because they have the capacity to reﬂect disease-relevant
biological activity and provide useful diagnostic and therapeutic
information. However, new biomarkers are needed to discriminate
between catabolic and maintenance events since many existinga Downing GJ, National Institutes of Health (US), United States, Food and Drug
Administration. Biomarkers and Surrogate Endpoints: Clinical Research and Applica-
tions. In: Proceedings of the NIH-FDA Conference Held on 15e16 April 1999 in Bethesda,
Maryland, USA. Downing GJ, Ed. Ofﬁce of Science Policy National Institutes of Health
Bethesda, Maryland, USA 2000 ELSEVIER Amsterdam.biomarkers reﬂect normal cartilage turnover, tissue repair, or
extracellular matrix (ECM) remodeling.
The recent proliferation of post-genomic technologies has
resulted in rapid growth and progress in biomarker research. Omic
technologies (i.e., genomics, transcriptomics, proteomics, metab-
olomics) are increasingly applied in biomarker discovery, especially
in the area of cancer biomarkers. Combinations of omic technolo-
gies, bioinformatics, advanced imaging and basic information such
as family history and genetic background may hold special promise
for the discovery of novel “combination biomarkers” that will form
the foundation for new diagnostic tests. These technologies are
likely to dominate the biomarker research arena and play
increasingly important roles in the identiﬁcation of new
biomarkers and their validation. The full complement of ECM
proteins has been described as the “core matrisome” comprising
w300 proteins in addition to ECM modifying enzymes, ECM-
binding growth factors, and other ECM-associated proteins10,11.
The cartilage ECM contains a limited number of molecules (Fig. 2).
Although this limits the total number of ECM proteins that may end
up in serum as biomarkers of joint disease and inﬂammation, the
processes of biomarker veriﬁcation, validation and qualiﬁcation
remain challenging, costly and time-consuming.
The “Year in Review” articles are becoming a well-established
tradition in Osteoarthritis and Cartilage. They provide a unique
opportunity to build on the “Year in Review” papers from the
previous years. This paper is a narrative review of the biomarker
papers published between the osteoarthritis research society
international (OARSI) 2011 Congress held from 15 to 18 September
2011 in San Diego, California and the OARSI 2012 meeting, held
from 26 to 29 April 2012 in Barcelona, Spain. It summarizes the
progress in the ﬁeld by reviewing the key published papers related
to OA biomarkers and continues a theme established by the “Year in
Review” papers from the 2010 and 2011 OARSI meetings12,13. The
methodology involved searching the PubMed/MEDLINE and Sci-
Verse Scopus bibliographic databases using the keywords
‘biomarker’ and ‘osteoarthritis’. In addition, the bibliographic
databases were searched using the keywords ‘biomarker’ and
‘proteomics’. The PubMed/MEDLINE literature search was con-
ducted using the Advanced Search Builder function (http://www.
ncbi.nlm.nih.gov/pubmed/advanced) and speciﬁcally focused on
Fig. 2. Schematic illustration of the cartilage matrisome. This ﬁgure illustrates the major molecular constituents of the ECM of articular cartilage and the physical and functional
association between its constituents. The molecules are arranged into large multi-molecular assemblies in the territorial and interterritorial ECM of chondrocytes. Adapted from
Heinegård and Saxne, 201175.
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papers were found with the keywords ‘biomarker’ and ‘osteoar-
thritis’ (Table I) and 15 papers included the keywords ‘biomarker’
and ‘proteomics’ (Table II). Review articles published in the same
period including the keywords ‘biomarker’ and ‘osteoarthritis’ are
summarized in Table III.
Selected OA biomarker studies published between 2011 and
2012
Table I summarizes the key papers published between
September 2011 and April 2012. Due to space and article length
limitations, it was not possible to review all these papers in great
detail. Therefore, only a selected number of papers from the last
8 months are discussed in the following sections.
The importance of large cohorts of human patients in OA
biomarker research is highlighted in a clinical study by van Spil and
co-workers14. In this study they quantitatively assessed a wide
spectrum of biomarkers in Cohort Hip and Cohort Knee (CHECK),
a large 10-year prospective cohort of 1,002 individuals with (very)
early symptomatic knee and/or hip OA. The authors examined 14
biomarkers by enzyme-linked immunosorbent assay (ELISA) or
radioimmunoassay (RIA) and used principal component analysis
(PCA) to analyze the data. This approach helped to ﬁve “clusters”,
consecutively designated as ‘bone-CTX-II’, ‘inﬂammation’, ‘syno-
vium’, ‘C1, 2C-adipokines’, and ‘cartilage synthesis’ clusters. Based on
their analysis they propose that urinary C-terminal telopeptide II
(uCTX-II) may be a marker of bone degradation as well as cartilage
degradation. They also suggest that cartilage oligomeric matrix
protein (COMP) in serum cartilage oligomeric matrix protein
(sCOMP) may reﬂect synovial changes rather than cartilage metab-
olism. Interestingly, the authors of this study propose thatadipokines have no major involvement in joint metabolism.
Although the results of this study will require validation by
complementary approaches, they do highlight the utility of PCA as
a quantitative tool for identifying “clusters” or “groups” of
biomarkers.
Animal models continue to have an impact on OA biomarker
research.Willett et al.,15 used the Hartley guinea pig (HGP)model to
demonstrate that increased advanced glycation endproducts
(AGEs) accelerate the progression of spontaneous OA. They
measured cartilage pentosidine, an established biomarker for AGEs
to show that enhanced levels of non-enzymatic glycation and
pentosidine cross-linking are involved in spontaneous OA
progression in this model.
STR/ort mice were used in a study by Braza-Boils et al., in which
serum levels of matrix metalloproteinase-3 (MMP-3) but not those
of tumor necrosis factor-alpha (TNF-a), interleukin 17 (IL-17) or
prostaglandin E(2) (PGE2) were found to correlate with histopath-
ological changes in knee joints16. This study adds to the consider-
able body of evidence implicating MMP-3 in early degenerative
changes in OA.
Another recent animal study highlights the utility of the dog as
an animal model of OA. Alam et al.,17 measured the levels of tartrate
resistant acid phosphatase (TRAP), matrix metalloproteinase-2
(MMP-2), and tissue inhibitor of MMP (TIMP)-2 in synovial ﬂuids
and sera from dogs with OA. This study suggests that TRAP, MMP-2,
and TIMP-2 in synovial ﬂuid and serum may help to identify early
phases of canine OA.
Garner and co-investigators18 measured the cytokine, chemo-
kine, and matrix metalloproteinase (MMP) proﬁles of synovial
ﬂuid, serum, and urine from dogs with surgically induced and
naturally occurring OAwere compared with dogs without OA using
xMAP technology. Biomarkers that exhibited signiﬁcant differences
Table I
Summary of selected OA biomarker studies (2011e2012)
Reference Study type and objectives Biomarker identiﬁed/proteins involved Species, tissue types, assays and techniques used Main outcome of the study
van Spil et al., 201214 Clinical study assessing a wide spectrum
of biomarkers in a large cohort of
individuals with (very) early
symptomatic knee
and/or hip OA
Fourteen biomarkers were assessed
by ELISA or RIA including uCTX-II,
uCTX-I, urinary N-telopeptide of type
I collagen (uNTX-I), sCOMP, N-terminal
propeptide of type IIA procollagen (sPIIANP),
sCS846, sC1, 2C, sOC, serum C-terminal
telopeptide of type I collagen (sPINP), sHA,
N-Terminal propeptide of type III collagen
(sPIIINP), pLeptin, pAdiponectin, pResistin
Human; CHECK, a 10-year prospective
cohort of 1,002 individuals with early
symptomatic knee and/or hip OA
PCA enabled identiﬁcation of ﬁve clusters,
consecutively designated as ‘bone-CTX-II’,
‘inﬂammation’, ‘synovium’, ‘C1,
2C-adipokines’, and ‘cartilage
synthesis’ cluster
uCTX-II may not only be a marker of
cartilage but also bone degradation
sCOMP may reﬂect synovial rather
than cartilage metabolism
No major involvement of adipokines in
joint metabolism was identiﬁed
Willett et al., 201215 Basic study testing the hypothesis that
increased AGEs accelerate the
progression of spontaneous OA
Cartilage pentosidine, an established
biomarker for AGEs
HGP model; see the primary article for
full details of assays and
techniques used
Enhanced levels of non-enzymatic
glycation and pentosidine
cross-linking are involved
in spontaneous
OA progression
AGEs accumulation due to intraarticular
ribose-containing injections in the HGP
model of spontaneous knee OA did not
enhance disease progression
Braza-Boils et al., 201216 Basic study of the early phases of
idiopathic OA in STR/ort mice
Serum levels of MMP-3 but not those
of TNF-a, IL-17 or PGE2 correlated with
histopathological changes in knees
of STR/ort mice
STR/ort mice; see the primary article for
full details of assays and
techniques used
MMP-3 is a sensitive biomarker for the
detection of early OA alterations
Garner et al., 201118 Clinical study in which the cytokine,
chemokine, and MMP proﬁles of synovial
ﬂuid, serum, and urine from dogs with
surgically induced and naturally occurring
OA were compared with dogs without OA
MCP-1, IL-8, KC, MMP-2 and MMP-3
were biomarkers that exhibited
signiﬁcant differences between
groups and their sensitivities
and speciﬁcities were calculated
to determine their diagnostic utility
Canine; multiplex bioassays (xMAP
technology e bead-based multiplexing
of up to 500 analytes per well)
This study used canine samples to provide
information relating to pro-inﬂammatory
cytokines, chemokines, and MMPs in OA,
and identiﬁed potential diagnostic
biomarker candidates
Weng et al., 201257 Clinical study aimed at screening serum for
biomarkers of knee
OA using a phage random peptide library
A phage clone with inserted peptide
TGLESGHGPGDS (named KOA1)
was identiﬁed
Human; a phage random peptide library
of random peptide 12-mers was
screened with puriﬁed
immunoglobulin G (IgG)
from sera of knee OA patients
The novel knee OA mimic peptide KOA1
could be a potential serum biomarker
for knee OA
Xu et al., 201226 Clinical study aimed at demonstrating
omentin-1 levels in serum and synovial
ﬂuid of patients with knee OA and to
investigate their correlation with
radiographic disease severity
according to the KL
grading system
Omentin-1 (also known as intelectin 1) Human; 197 patients with OA and 65
sex- and age-matched healthy controls
Omentin-1 in synovial ﬂuid might serve
as a potential biomarker for reﬂecting the
degenerative process in primary knee OA
González-Álvaro et al., 201120 The objective of this clinical study was to
determine whether sIL-15 levels could
serve as a biomarkers of disease severity
in patients with early OA
sIL-15 Human; see the primary article for full
details of assays and techniques used
IL-15 levels in serum may predict a severe
disease course in patients with early OA
McCoy et al., 2011 The aim of this animal study was to
investigate whether variations in the
level of Xylosyltransferase 1 (Xylt1)
present in serum can be used to
predict OA disease progression
Xylt1 Mouse; see the primary article for full
details of assays and techniques used
Serum Xylt1 level increase during early
posttraumatic OA
Cattano et al., 201121 The aim of this clinical study was to
determine if biochemical differences exist
between OA knees with and
without effusion
MMP-3, TIMP-1, TIMP-2, and IL-10 were
signiﬁcantly higher in the knees with
effusion than in the knees without effusion
Human; cross-sectional study consisting
of 22 volunteers (11 with knee effusion,
11 without knee effusion) with conﬁrmed
late-stage radiographic knee OA (KL
score > 3). Synovial ﬂuid samples
Biochemical differences were observed
between knees with and without effusion
suggesting the existence of OA subsets
characterized by distinct biochemical
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were collected and analyzed using
custom multiplex ELISAs
characteristics and clinical ﬁndings
(e.g., joint effusion)
Fernandez-Moreno et al., 201158 The aim of this clinical study was to assess
the incidence of the mtDNA haplogroups
on serum levels of two of the main
antioxidant enzymes, Manganese
Superoxide Dismutase (Mn-SOD
or SOD2) and catalase, and to
test the potential of these proteins as
OA biomarkers
Mn-SOD or SOD2 and catalase Human; 73 OA patients and 77 healthy
controls carrying the haplogroups J,
U and H, by ELISA assays
Increased levels of SOD2 were seen
in OA patients
Mitochondrial haplogroups signiﬁcantly
correlated with serum levels of catalase
Conrozier et al., 201222 The aim of the clinical study was to
investigate the effect of HA
intra-articular injections (IA)
on OA biomarkers in patients
with knee OA
uCTX-II and S-HA Human; see the primary article for full
details of patients and assays used
Ninety days after HA intra-articular
injections uCTX II levels signiﬁcantly
decreased compared to baseline
suggesting a slowdown of type II
collagen degradation
Song et al., 201227 The aim of this clinical study was to
develop a method to detect COMP
as an OA biomarker
COMP Human; FMGC-based immunoassay
and commercial ELISAs for COMP
FMGC-based immunoassay offers a new
approach for detecting COMP and other
clinically relevant OA biomarkers in
blood and synovial ﬂuid
Alam et al., 201117 The aim of this study was to measure
the levels of three biomarkers in
synovial ﬂuids and sera from
dogs with OA
TRAP, MMP-2, and TIMP-2 Canine; western blotting and ELISAs Assays for TRAP, MMP-2, and TIMP-2 in
synovial ﬂuid and serum, may identify
early phases of OA
Saetan et al., 201159 The objective of this clinical study was
to investigate interferon-g inducible
protein-10 (IP-10) concentrations in
plasma and synovial ﬂuid of patients
with knee OA and to analyze their
relationship with disease severity
Interferon-g, IP-10 Human; 40 OA patients and 15 healthy
controls
OA grading was performed according to
the KL criteria
IP-10 levels in plasma and synovial ﬂuid
were assessed by ELISA
Plasma and synovial ﬂuid
interferon-g IP-10 correlates
with radiographic severity
in knee OA
Duan et al., 201124 The aim of this clinical study was to
investigate visfatin levels in synovial
ﬂuids and plasma of patients with
primary knee OA and establish its
relationship with biomarkers of
cartilage degradation in synovial ﬂuid
Visfatin, type II collagen and aggrecan Human; 30 OA patients, 12 SF control,
and 12 plasma control subjects
Visfatin levels in synovial ﬂuid and
plasma were measured by ELISA
Radiographic grading of OA in the knee
was performed by the KL criteria
Visfatin positively correlated
with type II collagen and aggrecan
degradation
Visfatin may be involved in cartilage
matrix degradation
Streich et al., 201119 The aim of this study was to determine
the value of urinary biomarkers in the
diagnosis of chondral defects
after ACL rupture
Cross-linked uCTX-I, uCTX-II
and sCOMP
Human; 38 patients with previous ACL
rupture were included
uCTX-I, uCTX-II and sCOMP could
be used to identify patients with focal
cartilage lesions from an early stage of OA
Hao et al., 201125 The aim of this clinical study was to
investigate adiponectin levels in
plasma and synovial ﬂuids of
female patients with knee OA
and to analyze the correlation
between adiponectin and
degradation markers of
cartilage matrix in
synovial ﬂuid
Adiponectin Human; see the primary article for full
details of patients and assays used
Adiponectin may be involved in the
regulation of the degradation of cartilage
matrix in OA
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Table II
Summary of selected OA biomarker studies that speciﬁcally used proteomic tools and technologies (2011e2012)
Reference Study type Biomarker identiﬁed/proteins involved Species, tissue types, assays and techniques
used
Main outcome of the study
Wang et al., 2012 Basic study using genetically
engineered mice and three different
mouse models of OA
C5, C6, the complement regulatory protein
CD59a and the MAC
Expression of inﬂammatory and degradative
molecules was lower in chondrocytes from
destabilized joints from C5-deﬁcient mice than
C5-sufﬁcient mice, and MAC induced
production of these molecules in cultured
chondrocytes. MAC colocalized with MMP-13
and with activated ERK around chondrocytes in
human OA cartilage
Mouse; human; see the primary article for full
details
Dysregulation of complement in synovial joints
plays a key role in the pathogenesis of OA
Vincourt et al., 201260 Clinical study combined with in vitro
experiments
Matrilin-3 (MATN3) Human; synovial ﬂuid from human OA patients MATN3 switched from anti- to pro-anabolic
upon integration to the ECM
MATN3 downregulated cartilage ECM synthesis
and upregulated catabolismwhen administered
as a soluble protein
Mateos et al., 201251 Clinical study of synovial ﬂuids from OA
and RA patients
Pooled RA samples: proteins related to
complement activation, inﬂammation and the
immune response (major MMPs and several
neutrophil-related proteins)
Pooled OA samples: ﬁbronectin, kininogen-1,
cartilage acidic protein 1 and COMP
Human; immunodepletion, size fractionation,
in-gel digestion, reverse-phase peptide
separation, MALDI-TOF/TOF, and spectral
analysis
One hundred and thirty-six different proteins
were identiﬁed in synovial ﬂuid Some of the
proteins identiﬁed are likely to be involved in
the etiopathogenesis of RA and OA as putative
disease biomarkers and their presence in
synovial ﬂuid may be a prelude to their dilution
in serum
Onnerfjord et al.,
201261
Basic study describing the
compositional analysis of ECM proteins
in articular cartilages, meniscus,
intervertebral disc, rib and tracheal
cartilages by relative quantiﬁcation
Compared the relative abundance of
150 proteins
Matrilin-1 and epiphycan in rib and trachea.
Asporin in the meniscus. Lubricin in the nucleus
pulposus of the intervertebral disc. Asporin,
CILP and COMP were difﬁcult to extract may be
cross-linked
Human; tissue extraction, trypsin digestion, 2D
LC-separations coupled to tandem mass
spectrometry, relative quantiﬁcation with
isobaric labeling, iTRAQ
Distinct differences in protein patterns may
relate to different tissue mechanical properties,
and to the intriguing tropism in different
patterns of joint pathology
Sun et al., 201262 Clinical study of human patients with
ankylosing spondylitis (AS), RA and OA
Alpha 1-anti-trypsin (ATA1) expression was
increased synovial membranes of AS compared
with samples from RA and OA
Human; western blotting;
immunohistochemistry; Q-PCR (Taqman
method)
The study reports increased expression of ATA1
in the synovial tissues of patients with AS
Chiaradia et al., 201263 Clinical study of equine OA and
osteochondrosis (OC) using equine
synovial ﬂuids
Proteins involved in inﬂammation, coagulation,
oxidative stress and matrix damage
Equine; differential proteomic analysis Deregulated proteins in OA and OC included
inﬂammatory components, coagulation
pathways, oxidative stress and matrix damage,
suggesting pathological alterations in articular
homeostasis, plasma-synovial ﬂuid exchange,
joint nutritional status and vessel permeability
Katano et al., 201164 Clinical study using synovial ﬂuids from
OA and RA patients
S100 calcium-binding protein A8 (S100A8) Human; ELISA; antibody arrays; real-time PCR S100A8 was signiﬁcantly elevated in synovial
ﬂuids of patients with RA compared to OA
patients and may be involved in the
exacerbation of RA
Calamia et al., 201164 Basic study of protein modiﬁcations
inuced by the pro-inﬂammatory
cytokine IL-1b
Cellular chaperones were upregulated
concurrent with a down-regulation of the actin
cytoskeleton
Upregulated by IL-1b: pro-inﬂammatory
mediators, proteases and proteins involved in
the transforming growth factor-beta (TGF-b)
pathway
Downregulated by IL-1b: aggrecan vitamin K-
dependent proteins and thrombospondin
Human; stable isotope labeling with amino
acids in cell culture (SILAC) technique
Metabolic labeling of chondrocytes enables the
quantitative analysis of changes induced by IL-
1b treatment
Pan et al., 201165 Clinical study exploring the use of
proteomic methods for the
identiﬁcation of OA biomarkers
No speciﬁc proteins identiﬁed; two peptide
peaks were found as potential diagnostic
markers for OA
Human; MALDI-TOF-MS This study highlights the value of proteomic
methods for identiﬁcation of potential
biomarkers of OA
Fernandez-Puente et al.,
201166
The aim of this study was to identify
novel protein biomarkers of moderate
and severe OA in serum
Complement components, lipoproteins, von
Willebrand factor, tetranectin, and lumican
Human; sera from 50 moderate OA patients, 50
severe OA patients, and 50 non-symptomatic
controls. Serum protein levels were analyzed
using isobaric tags for relative and absolute
quantitation (iTRAQ) and MALDI-TOF/TOF MS
A number of biomarkers were identiﬁed but the
speciﬁcity and selectivity of these candidates
need to be validated before new molecular
diagnostic or prognostic tests for OA
can be developed
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Table III
Review articles published including the keywords ‘biomarker’ and ‘osteoarthritis’ (2011e2012)
Reference Purpose of the review
Rousseau and Garnero,
201267
The aim of this review was to use the BIPED classiﬁcation that appeared in 2006 for OA biomarkers to describe the potential usage of
particular biomarkers
Patra and Sandell, 20119 This review highlights some of the biochemical biomarkers in current use in OA, their applications and limitations
The authors highlight the potential of omics technologies such as lipidomics and metabolomics for detecting early phenomena in OA
Henrotin 201213 This review is a summary of selected studies related to soluble biomarkers published between 1 September 2010 and 30 August 2011
identiﬁed through a PubMed search using the terms “biomarker” and “osteoarthritis”
Patra and Sandell, 201168 This paper reviews recent advances in OA biomarkers and discusses the application of proteomic technologies that have generated
several new, non-conventional biomarkers that could allow better proﬁling of OA
The authors propose that biomarker combinations have the ability to subgroup the heterogenous OA population to allow a better
scrutiny of diagnosis and treatment options
van der Kraan and van den
Berg 201269
This paper comprehensively and elegantly reviews the literature on the role and regulation of chondrocyte terminal differentiation
(hypertrophy-like changes) in OA and integrates this information in a conceptual model of primary OA development
Hoch et al., 201170 The purpose of this systematic review and meta-analysis was to answer the following questions:
(1) Is sCOMP elevated in patients with radiographically diagnosed knee OA compared to controls?
(2) Are there differences in sCOMP levels when comparing differing radiographic OA severities to controls?
The authors conclude that sCOMP is elevated in patients with knee OA and is sensitive to OA disease progression and future research
studies with a higher level of evidence should be conducted to investigate the use of this biomarker as an indicator for OA development
and progression
Madry et al., 201271 The aim of this systematic review was to highlight the molecular basis and histopathological features of early OA
Special emphasis is placed on early changes in subchondral bone and other structures of the joint, such as the menisci, the synovial
membrane, the joint capsule, ligaments, muscles and the infrapatellar fat pad
Claessen et al., 201272 In this paper the authors conducted a systematic review of reported associations between circulating insulin-like growth factor-1 (IGF-1)
and/or IGF-1 gene polymorphisms and radiographic OA
No association was found between serum IGF-1 and the occurrence of radiographic OA (moderate level of evidence), and a positive
relationship between IGF-1 gene polymorphisms and radiographic OA (moderate level of evidence); however the confounding effect of
BMI was insufﬁciently addressed
The authors propose that future well-designed prospective studies should further elaborate the role of the complex GH/IGF-1 system in
primary OA
Gharbi et al., 201173 The aim of this elegant review was to gather most of the available information relating to proteomic techniques and their applications to
OA research
Mobasheri 201174 This perspective article discusses the relevance and potential of proteomics for studying age-related musculoskeletal diseases such as OA
and reviews the contributions of key investigators in the ﬁeld
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[MCP-1], interleukin-8 [IL-8], keratinocyte-derived chemo-
attractant [KC], MMP-2 and MMP-3. The sensitivities and speciﬁc-
ities of these markers were also calculated to determine their
diagnostic usefulness in a future biomarker panel. Interestingly,
synovial ﬂuid IL-8 was the most sensitive of the markers although
MCP-1 was also highly sensitive and speciﬁc. The authors propose
that this “panel” of biomarkers may differentiate between cruciate
disease and other types of OA. This is a novel and interesting
concept that should be borne in mind in our future studies on OA
biomarkers.
A similar study carried out by Streich et al., 201119 in humans
determined the value of urinary biomarkers in the diagnosis of
chondral defects after anterior cruciate ligament (ACL) rupture. The
authors measured the levels of cross-linked C-terminal telopeptide
I (uCTX-I), uCTX-II and sCOMP in human patients with previous ACL
rupture were included. The results suggest that these biomarkers
may be used to identify patients with focal cartilage lesions from an
early stage of OA.
González-Álvaro et al.,20 determinedwhether interleukin-15 (IL-
15) levels in serum IL-15 (sIL-15) could serve as useful biomarkers of
disease severity in patients with early OA. The authors performed
multivariate longitudinal analyses to show that sIL-15 may predict
a severe disease course in patients with early OA and this group of
patients may beneﬁt from receiving intensive treatments. This
study also reminds us that there may be temporal and joint speciﬁc
changes in the expression of certain cytokines in OA.
A study by Cattano et al.,21 examined biochemical differences
between OA knees with and without effusion. The authors
measured MMP-3, TIMP-1, TIMP-2, and interleukin-10 (IL-10) and
found these to be signiﬁcantly higher in the knees with effusion
than in the knees without effusion. The measurements were doneusing custom multiplex ELISAs on synovial ﬂuid samples. This
study highlights the fact that joint effusions are important
inﬂammatory events in subsets of OA patients and may be char-
acterized using distinct biochemicals.
Intraarticular injections are important treatments for patients
with knee OA. Recent work by Conrozier et al.,22 investigated the
effect of intraarticular injections with hyaluronic acid (HA) on
urinary type II collagen C-telopeptide (uCTX-II) and serum hyalur-
onic acid (S-HA). These two markers signiﬁcantly decreased
compared to baseline in treated patients suggesting that HA may
hinder the degradation of type II collagen in knee OA. It is likely that
intraarticular injections with HA and corticosteroids can help
subsets of patients with knee OA. Therefore biomarkers that can
demonstrate the effectiveness of intraarticular injections can help
to further develop and improve intraarticular formulations for
cohorts of patients who may beneﬁt from such treatments.
Visfatin is a newly discovered adipocyte hormone (adipokine)
with a direct relationship between plasma visfatin level and type 2
diabetes mellitus. Visfatin was originally cloned as a putative cyto-
kine shown to enhance the maturation of B cell precursors in the
presence of interleukin-7 (IL-7) and stem cell factor, it was therefore
named “pre-B cell colony-enhancing factor” (PBEF)23. Visfatin is
also known as nicotinamide phosphoribosyltransferase e an
enzyme that catalyzes the condensation of nicotinamide with
5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mono-
nucleotide, an intermediate in the biosynthesis of nicotinamide
adenine dinucleotide (NAD). It is the rate-limiting component in the
mammalian NAD biosynthesis pathway. A clinical study by Duan
et al.,24 investigated visfatin levels in synovial ﬂuids and plasma of
patients with primary knee OA and established its relationship with
biomarkers of cartilage degradation in synovial ﬂuid. Visfatin posi-
tively correlated with the degradation of type II collagen and
b http://www.genecards.org/cgi-bin/carddisp.pl?gene¼FSTL1.
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cartilage matrix degradation. Further clinical and basic studies are
required in to unravel the role of visfatin in joint inﬂammation and
cartilage degradation.
Another study by Hao et al., 201125 also focused on adipokines
by investigating adiponectin levels in plasma and synovial ﬂuids of
female patients with knee OA. Adiponectin is an important adipo-
kine involved in the control of fat metabolism and insulin sensi-
tivity, with anti-diabetic, anti-atherogenic and anti-inﬂammatory
activities. The aim of this study was to analyze the correlation
between adiponectin and markers of cartilage matrix degradation
in synovial ﬂuid. Adiponectin may be involved in the regulation of
the degradation of cartilage matrix in OA. It is possible that adi-
ponectin may be involved in anti-inﬂammatory activities in
early OA.
Omentin-1 (also known as intelectin 1) is an adipokine that is
predominantly expressed in visceral adipose tissue. The levels of
omentin-1 mRNA are signiﬁcantly higher in visceral adipose tissue
compared to other types of adipose tissues. Although omentin-1
has been shown to have no effect on basal glucose uptake in
adipocytes, it does enhance insulin-stimulated glucose uptake and
increases AKT (protein kinase B) phosphorylation. Therefore, this
adipokine has the capacity of modulating glucose metabolism and
insulin signaling. Xu et al.,26 used ELISAs to measure omentin-1
levels in serum and synovial ﬂuid of patients with knee OA and
correlated the values with radiographic disease severity using the
KellgreneLawrence (KL) grading system. There were no signiﬁcant
differences in serum omentin-1 levels between patients with OA
and healthy controls. There were also no signiﬁcant differences in
serum omentin-1 levels among patients with OA with different KL
grades. However, synovial ﬂuid omentin-1 levels decreased
signiﬁcantly as the KL grades increased. The negative correlation
between synovial ﬂuid levels of omentin-1 levels and radiographic
severity of knee OA suggests that synovial omentin-1 is a biomarker
reﬂecting degenerative processes in the knee.
The studies by Duan et al.,24, Hao et al.,25 and Xu et al.,26 suggest
that adipokines are involved in various forms of OA whereas the
study by van Spil and co-workers14 suggests that adipokines are not
involved in cartilage metabolism. Clearly, this is an active area of
research and further studies are required to explain the differing
outcomes of these studies.
Technological and methodological advances are important for
progress in OA biomarker research. Song et al.,27 developed
a method to detect COMP using ﬂuoro-microbead guiding chip
(FMGC)-based immunoassays and compared it with commercial
ELISAs for COMP. The FMGC-based immunoassay clearly distin-
guished immunospeciﬁc from nonspeciﬁc binding and thus offers
a new approach for detecting COMP and other clinically relevant OA
biomarkers in human blood and synovial ﬂuid.
Fibulin-3 peptides (Fib3-1 and Fib3-2) e potential biomarkers
of OA
One of the most exciting discoveries over the last year has been
the identiﬁcation of ﬁbulin peptides in sera from OA patients.
Fibulins are a family of proteins that belong to a multigene family
with seven members. They are associated with basement
membranes and the ECM28. They are secreted glycoproteins that
become incorporated into a ﬁbrillar ECM. The known members of
the ﬁbulin family share an elongated structure with many calcium-
binding sites, owing to the presence of tandem arrays of epidermal
growth factor (EGF)-like domains29. They have overlapping binding
sites for basement-membrane proteins, ﬁbrillin, ﬁbronectin and
proteoglycans, and they participate in diverse supramolecular
structures. The amino-terminal portion of ﬁbulins contain repeatedelements with potential disulﬁde loop structure resembling that of
the complement component anaphylatoxins C3a, C4a, and C5a as
well as proteins of the albumin gene family and the remaining
portion of the molecules consists of a series of EGF-like repeats29.
There are reports of animal models of ﬁbulin deﬁciency and human
ﬁbulin gene mutations28. However, little is known about the
pathological roles of members of this family.
Recent studies by Henrotin and co-workers suggest that ﬁbulin-
3 peptides (Fib3-1 and Fib3-2) are potential biomarkers of OA30.
Fibulin 3 is also known as epidermal growth factor-containing
ﬁbulin-like extracellular matrix protein-1 (EFEMP1) and epidermal
growth factor (EGF) containing ﬁbulin-like ECM protein. The
EFEMP1 gene encodes a protein that contains tandemly repeated
EGF-like repeats followed by a C-terminus ﬁbulin-type domain. The
protein can bind the EGF-receptor (EGFR), inducing EGFR auto-
phosphorylation and activating downstream signaling pathways. It
may also function as a negative regulator of chondrocyte differen-
tiation. The authors set out to identify new OA biomarkers by using
proteomics. They focused on differentially expressed proteins and
found that Fib3-1 and Fib3-2 are present in cartilage and serum of
OA patients. They used immunoassays to study the distribution of
Fib3-1 and Fib3-2 in cartilage and developed speciﬁc immunoas-
says to detect and quantify them. Expression of both peptides was
signiﬁcantly elevated in the superﬁcial layer of ﬁbrillated cartilage
from OA patients. This study is a good example of how a proteo-
mics-based workﬂow can be applied in new OA biomarker
discovery. The authors compared urine samples from women with
OA and healthy age-matched controls to quantify differentially
expressed proteins by employing differential in gel electrophoresis
(DIGE). They identiﬁed two ﬁbulin (Fib) peptides as increased in OA
samples. Speciﬁc ELISAswere developed against these peptides and
validated in a larger population of patients. The data from Henrotin
et al., suggest that both Fib3-1 and Fib3-2 can be used to discrim-
inate normal and OA samples population, and thus both peptides
are potential biomarkers of OA.
Follistatin-like protein 1 (FSTL1): a novel OA biomarker in
serum
Recent work suggests that FSTL1 is a serum OA biomarker with
the capacity to reﬂect the severity of joint damage in OA patients31.
FSTL1 is a secreted glycoprotein that has been implicated in
arthritis. The FSTL1 gene encodes a protein similar to follistatin, an
activin-binding protein. FSTL1 contains an FS module, a follistatin-
like sequence containing 10 conserved cysteine residues. The FSTL1
protein has a multi-speciﬁc binding nature; it can bind heparin and
may modulate the action of TGF-b superfamily growth factors on
cell proliferation and differentiation32. This gene product is thought
to be an autoantigen associated with RA33,34, b. It is overexpressed
in RA synovium, the product of which exerts inhibitory activity on
synovial cell growth. FSTL1 is expressed in the synovial tissues of
RA, but its polymorphisms are not associated with genetic
susceptibility35. Although new polymorphic sites have been iden-
tiﬁed for this gene, they are not speciﬁcally associated with
susceptibility to RA, suggesting that overexpression of FSTL1 is
a secondary consequence of inﬂammatory changes in the synovial
environment of RA. In addition, FSTL1 is upregulated in the early
stages of collagen-induced murine arthritis and it can exacerbate
the disease when delivered by gene transfer36. It is overexpressed
in human arthritis and its neutralization inhibits murine collagen-
induced arthritis and suppresses interferon-gamma (IFN-gamma)
and chemokine 10 (CXCL10) production in arthritic joints36.
Fig. 3. The MAC of complement. The MAC is a multi-molecular assembly, which
involves the following proteins: C5, C6, C7, C8, and C9. These proteins participate
directly in the killing of target cells37. The formation of this complex is toxic to
chondrocytes39 and has been implicated in OA38,51 and RA40e43.
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FSTL1 expression in OA cartilage and synovium and assess its
potential utility as a biomarker of joint damage in OA patients. They
detected FSTL1 expression by real-time polymerase chain reaction
(PCR), western blot and immunohistochemistry in articular carti-
lage and synovial tissues from OA patients and control patients
without OA (age-matched trauma samples). The concentration of
FSTL1 in serum and synovial ﬂuid was measured by ELISA assays in
OA and control samples. FSTL1 mRNA and protein levels were
elevated in the synovial tissues from OA patients compared with
control trauma patients. FSTL1 was strongly expressed in the
cytoplasm of synovial cells and capillary endothelial cells, but its
expressionwas weak in chondrocytes fromOA cartilage. Serum and
synovial FSTL1 concentrations were signiﬁcantly elevated in OA
patients compared to controls. Interestingly, serum and synovial
FSTL1 levels were higher in female OA patients. Serum FSTL1 levels
in female OA patients statistically correlated with KL grade, joint
space narrowing (JSN) and the Western Ontario McMaster and
Universities Osteoarthritis (WOMAC) indices. Serum FSTL1 levels
also correlated signiﬁcantly with age and disease progression.
FSTL1 is known to be upregulated in RA. This study suggests that
this protein may a potentially useful serum biomarker in OA
patients as well. The authors suggest that FSTL1 that may reﬂect the
severity of joint damage, andmay have potential for monitoring the
course of disease progression and the efﬁcacy of new pharmaco-
therapies in OA patients31.
FSTL1 plays a central role in arthritic diseases by enhancing IFN-
g signaling pathways and activating cellular and molecular mech-
anisms that bridge innate and adaptive immune responses36.
Elevated serum FSTL1 levels is associated with both OA31 and RA33.
It reﬂects not only joint diseases but also inﬂammation and tissue
degradation in systemic autoimmune diseases33. Serum FSTL1
levels may thus serve as a serological inﬂammatory marker of
disease activity in OA and RA patients and may form the basis of
new biomarker assays.
Complement proteins as membrane biomarkers of OA
The complement system consists of a large array of proteins that
interact in a carefully regulated manner to destroy invading
microorganisms and prevent the deposition of immune complexes
in healthy tissues. Complement can be activated by diverse mech-
anisms signaling through distinct pathways. However, the key
players involved in killing cells are just ﬁve proteins: C5b, C6, C7, C8
and C9. Although none of these possess enzymatic, proteolytic or
lipolytic activity, they converge on a ﬁnal common pathway and
assemble into a multi-molecular complex known as the membrane
attack complex (MAC)37. MAC is typically formed as a result of the
activation of the alternative pathway of the complement system, as
one of the effector systems of the immune system. MAC forms
transmembrane channels that disrupt the phospholipid bilayer of
target cells, leading to cell lysis and cell death (Fig. 3). A number of
complement proteins participate in the assembly of the MAC. The
ﬁrst step involves binding of activated C5b to C6 to form a
C5b-6 complex. This complex then binds to C7 forming the C5b-7
complex. The C5b-7 complex then binds to C8 forming the
C5b-8 complex. C5b-8 subsequently binds to C9 and acts as
a catalyst in the polymerization of C9. The active MAC complex
consisting of C5b-C6-C7-C8-C9 then inserts into target cell
membranes to form a functional pore, resulting in ion ﬂux and
ultimately osmotic cell lysis.
Traditionally OA has been viewed as a biomechanical disease
resulting from ‘wear and tear’ and the breakdown of articular
cartilage in synovial joints. Recent research has focused on the role
of inﬂammation in OA and evidence for an inﬂammatorycomponent to OA is increasing despite OA often being regarded as
a mechanical and non-inﬂammatory disease. Recent work byWang
and co-workers suggests that the ‘MAC’ component of complement
is involved in the pathogenesis of OA and complement proteins are
aberrantly expressed in OA38. The authors attempted to clarify the
role of low-grade inﬂammation in OA by identifying a central role
for the complement system in disease pathogenesis. Proteomic and
transcriptomic analyses of synovial ﬂuids and membranes from
individuals with OA revealed that the expression and activation of
complement is abnormally high in human OA joints. The authors
used knockout mice genetically deﬁcient in complement compo-
nent 5 (C5), C6 or the complement regulatory protein CD59a to
show that the MAC component of complement is important for
disease development in three different murine models of OA.
Expression of inﬂammatory and matrix degrading molecules was
lower in chondrocytes from destabilized joints from C5-deﬁcient
mice and MAC induced production of these molecules in cultured
chondrocytes. The authors used immunohistochemistry and
immunoﬂuorescence techniques to colocalize MAC with matrix
metalloproteinase-13 (MMP-13) and with activated extracellular
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cartilage.
We have known for more than 20 years that complement is
involved in RA and is toxic to chondrocytes39. MAC is an initiating
mediator inducing the inﬂammation associated with RA40.
Complement activation contributes to pathological processes in
a number of autoimmune and inﬂammatory diseases, including
RA41. Other researchers have previously suspected that comple-
ment may be involved in the pathogenesis of arthritis because
cartilage from patients with RA and from animals with antigen-
induced arthritis is frequently contaminated with complement-
containing immune complexes42. A possible role for complement
in cartilage degradation was modeled by Satsuma and co-workers
in 199339. They carried out in vitro experiments by exposing
chondrocytes to homologous serum, and determining cytotoxicity.
Complement activation was found to be highly cytotoxic and the
toxicity can be ablated by heat or methylamine treatment but not
by ethylene glycol tetraacetic acid (EGTA), suggesting that alternate
route of complement is involved in the pathogenesis of cartilage
degradation in inﬂammatory arthritis. However, the international
team of Wang and co-workers38 was the ﬁrst to shown that
inhibiting the complement system could help slow disease
progression in OA. Their data provides novel and mechanistic
evidence linking the dysregulation of complement in synovial
joints and the pathogenesis of OA38. Furthermore, the pharmaco-
logical modulation of complement that they carried out in wild-
type mice conﬁrmed the results obtained with mice genetically
deﬁcient in complement proteins.
The accumulating evidence suggests that activation of the
complement system is a dynamic calcium dependent process that
occurs in both OA and RA. This opens up novel and potentially
disease-modifying strategies for developing drugs capable of tar-
geted and controlled inhibition of complement for the treatment of
inﬂammation in OAc. The tantalizing possibility of controlled
pharmacological manipulation of various components of the
complement system is encouraging news for the pharmaceutical
industry at a time when economic pressures have forced the
closure of OA research divisions in many drug companies and the
abandonment of OA as a difﬁcult disease target. The interesting and
exciting paper by Wang and colleagues provides a much needed
boost and reinvigorates the development of therapeutic strategies
for targeting the inﬂammatory components of complement and
may result in drugs capable of controlling joint inﬂammation and
preventing joint destruction43.
Post-translational modiﬁcations in ECM molecules e
deamidated COMP
There is increasing interest in post-translational modiﬁcation of
ECMmacromolecules. Post-translational modiﬁcations increase the
complexity of the proteome by increasing the molecular variants of
proteins. The modiﬁed protein in turn may have altered biochem-
ical, enzymatic and physiological functions and may participate in
disease processes. There are numerous types of post-translational
modiﬁcations and these can be classiﬁed into natural and synthetic
sub-groups. Natural post-translational modiﬁcations include
phosphorylation, methionine oxidation, deamidation, glycosylation
and ubiquitination. Traditionally phosphorylation of chondrocyte
proteins has been studied in the context of cell signaling and it is
well-known that the load-bearing properties of many ECM
macromolecules are the consequence of sulfation and glycosylation.c Haas MJ. Big MAC attack in osteoarthritis. SciBX 2011;4(47). http://dx.doi.org/10.
1038/scibx.2011.1311.Deamidation is a common post-translational modiﬁcation that
results in the conversion of an asparagine residue to a mixture of
isoaspartate and aspartate residues. Deamidation is a biologically
signiﬁcant phenomenon in a large percentage of cellular
proteins44. Deamidation causes time-dependent changes in the
charge and conformation of peptides and proteins44 and has been
described as a ‘molecular timer’ that controls protein turnover45.
It is well-established that ECM proteins age, as does cartilage.
During the aging process ECM molecules accumulate non-enzy-
matic post-translational modiﬁcations that cannot be reversed or
repaired. In an elegant recent study Catterall and co-workers
hypothesized that post-translational modiﬁcations could be
used to monitor the loss of ECM macromolecules in OA46. To test
this hypothesis, they focused on COMP, a well-established OA
biomarker and predicted sites of deamidation, which were
conﬁrmed, by mass spectroscopy (MS). They found evidence for
the presence of deamidated (Asp(64)) and native (Asn(64)) in
COMP and calculated the relative contribution of deamidated
COMP (D-COMP) to native COMP in cartilage. In addition, they
developed a new D-COMP-speciﬁc ELISA using the monoclonal
antibody 6-1A12An. The ELISA assay was used to study D-COMP
levels in the serum of patients undergoing joint replacement
surgery. Interestingly, they found that serum D-COMP but not
total COMP declined signiﬁcantly after joint replacement,
demonstrating a joint tissue source for D-COMP. The study was
further strengthened by analysis of 450 participants from the
Johnston County OA Project, a population-based study of knee
and hip OA in rural North Carolina47. In this study, controlling for
age, gender, and race, allowed D-COMP to be associated with
radiographic hip but not knee OA severity. In contrast, total COMP
was associated with radiographic knee but not hip OA severity. D-
COMP levels were higher in extracts from hip cartilage proximal
to OA lesions compared with samples from sites remote from the
lesions. Although total COMP did not vary by joint site or prox-
imity to the lesion, D-COMP did.
Previous studies of participants from the Johnston County OA
Project have shown that s-COMP reﬂects the presence, severity and
multiple joint involvement in OA by distinguishing an OA-affected
subgroup from an unaffected subgroup48. Serum COMP may be
useful as a biomarker of pre-radiographic hip joint pathology49 and
its levels also vary by ethnicity and sex50. The study by Catterall
et al., reﬁnes and enhances the previous work in this area by
focusing on the utility of D-COMP as an OA biomarker. The authors
demonstrate, for the ﬁrst time, that post-translational modiﬁca-
tions in COMP are important and are linked with aging and the
disease process. D-COMP appears to be the ﬁrst biomarker to show
speciﬁcity for a particular joint site. The presence and enrichment
of D-COMP in articular cartilage and the systemic circulation opens
up new possibilities for studying post-translational modiﬁcations
in other cartilage ECM macromolecules, and the development of
new assays capable of estimating the ratio between total the
amount of protein and the post-translationally modiﬁed fraction.
The authors propose that this reﬂects a fundamental underlying
difference between hip and knee cartilage turnover and repair
responses in OA and the deamidated epitope in hip OA cartilage
indicates a lesser repair response of hip OA compared with knee OA
cartilage.
This elegant and original article from the Kraus group highlights
how it makes sense both ‘biologically’ and ‘systemically’ to develop
assays for biologically relevant post-translational modiﬁcations. D-
COMP may turn out to be a longitudinal marker for following
disease progression within a human subject or a cohort of patients.
The D-COMP assay may also detect occult or pre-radiographic hip
disease. The future is looking bright for OA biomarker research
especially if more intuitive approaches such as this are employed.
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Quantitative and high-throughput proteomic techniques have
made important contributions to the discovery of complement
components, lipoproteins and lower-abundance ECM components
in body ﬂuids from OA patients. Table II summarizes some of the
key papers published between September 2011 and April 2012.
One of the most interesting clinical proteomics papers was
published by Mateos et al.,51. The authors used high performance
liquid chromatography (LC) coupled to MS [LC-matrix-assisted
laser desorption/ionization time-of-ﬂight (MALDI-TOF)/TOF] to
identify differentially expressed proteins in the synovial ﬂuid of OA
and RA patients51. The strategy they used involved pooling 20
samples from each disease state into OA and RA groups. According
to the authors, this was done to “reduce the contribution of
extreme individual values”. Samples were immunodepleted and
the most abundant plasma proteins were selectively removed to
enrich the lower-abundance proteins. The samples were then
subjected to protein size fractionation, in-gel digestion and reverse-
phase peptide separation in a nano-LC system. Peptide identiﬁca-
tion was done using a MALDI-TOF/TOF system. This strategy led to
the identiﬁcation of 136 different proteins. Spectral counting
revealed a greater abundance of proteins involved in complement
activation, inﬂammation and the immune response. In addition to
MMP-1 and several neutrophil-related proteins they identiﬁed
elevated levels of ﬁbronectin, kininogen-1, cartilage acidic protein
1 and COMP. The authors veriﬁed the results obtained for MMP-1,
transforming growth factor-beta-induced protein (BGH3), ﬁbro-
nectin and gelsolin by western blotting. Mateos et al., conclude that
this clinical proteomics approach may help identify novel proteins
and putative disease-relevant biomarkers51. The elevated levels of
these proteins in synovial ﬂuid may be linked to the etiopatho-
genesis of RA and OA and a prelude to increased levels of the
protein in serum. This study pushes the boundaries and sets new
standards for clinical studies of OA patients using proteomics.
Combining proteomics and microscopic imaging
A new technique known as MALDI imaging mass spectrometry
(IMS) has been developed for correlating protein expression to
speciﬁc anatomical areas of joint tissues52. This technology has
been applied to the analysis of synovial tissues from OA and RA
patients. This new technique is powerful and allows morphological
data from synovial tissue to be combined and correlated with
proteomics. A pathologist initially examines photomicrographs of
the stained tissue images and areas of interest are marked digitally.
The histology-annotated images are then merged to form a photo-
micrograph of the section taken before the application of MALDI.
Proteins identiﬁcations are then linked back to the anatomical
locations. MALDI IMS is a powerful tool for the rapid in situ
detection of proteins in cartilage and synovial tissue sections52.
Further reﬁnements in this technology and the addition of quan-
titative capability will make this one of the most powerful tech-
nologies in future studies of OA biomarkers.
Conclusions
The incidence of OA is steadily rising throughout the world not
only in the aging population, but also in middle-aged individuals.
Cartilage degradation and structural changes in subchondral bone
result in the production of fragments of ECM molecules. Many of
these are well-known biochemical markers or “biomarkers”.
Biomarkers may be useful markers of disease progression and can
be detected in blood, serum, synovial ﬂuid, and urine using tradi-
tional biochemical and immunological assays.Systems biology is increasingly applied in orthopedics and
rheumatology to cartilage and synovium. “Omics-based” technol-
ogies used in systems biology hold special promise for identifying
new biomarkers. These techniques include genomics, tran-
scriptomics, proteomics, metabolomics, glycomics, and bio-
informatics and can be applied to the study of cartilage, synovium,
synovial ﬂuid, and even blood (serum) or urine from OA patients.
Current “omics-based” research aims to develop an “analytical
toolbox”, which is hoped will contribute to the clinical develop-
ment process53,54.
Proteomics involves the application of specialized analytical
techniques that allow the evaluation of the protein composition
of tissues, cells, and culture supernatants. Proteomics is being
increasingly applied in basic cartilage biology and OA research.
Proteomic screening techniques are also making signiﬁcant
contributions to the discovery of novel OA biomarkers in serum
and urine. Many of the biomarkers identiﬁed indicate normal
cartilage turnover, tissue repair, or ECM remodeling whereas
others reﬂect catabolic events during the process of cartilage
degradation in the later stages of OA. However, there is a need for
standardization and consensus guidelines for clinical proteomics.
These techniques require further development, standardization,
clinical testing and validation. Future progress will require
deposition of proteomic datasets in publicly accessible databases
and archives. At the present time the databases are too small and
contain scant data. Expanding the databases will allow more
detailed bioinformatic studies. Combining biochemical markers
with tissue and cell imaging techniques and innovative bio-
informatic approaches (i.e., machine learning, clustering, data
visualization) are likely to increase the predictive power of future
‘combination biomarkers’.
Post-translational modiﬁcations are biologically signiﬁcant
phenomena in a large percentage of proteins. Future research
should focus on post-translational modiﬁcations of cartilage ECM
proteins with aging and OA. Some post-translational modiﬁcations
serve as ‘molecular timers’ that control protein turnover and are
likely to have pathophysiological relevance to OA and other joint
diseases.
Biomarkers reﬂect diverse biological activities. It is therefore
important to discriminate between catabolic and maintenance
events. The deﬁnition of ‘biomarker’ will need to reﬂect these
diverse processes and the validation and qualiﬁcation processes for
novel biomarkers will ultimately depend on the context and
speciﬁc purpose of their intended applications. New biomarkers
require validation according to the Burden of Disease, Investigative,
Prognostic, Efﬁcacy of Intervention and Diagnostic and Safety
(‘BIPEDS’) criteria for detecting early, pre-radiographic changes in
joints55. Combinations of existing and new biomarkers may
improve their prognostic accuracy and help identify at-risk
patients56.
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